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Fhf2 gene deletion causes temperature-sensitive
cardiac conduction failure
David S. Park1,*, Akshay Shekhar1,*, Christopher Marra2,3,*, Xianming Lin1, Carolina Vasquez1, Sergio Solinas4,
Kevin Kelley5, Gregory Morley1, Mitchell Goldfarb2 & Glenn I. Fishman1
Fever is a highly conserved systemic response to infection dating back over 600 million years.
Although conferring a survival benefit, fever can negatively impact the function of excitable
tissues, such as the heart, producing cardiac arrhythmias. Here we show that mice lacking
fibroblast growth factor homologous factor 2 (FHF2) have normal cardiac rhythm at baseline,
but increasing core body temperature by as little as 3 C causes coved-type ST elevations and
progressive conduction failure that is fully reversible upon return to normothermia.
FHF2-deficient cardiomyocytes generate action potentials upon current injection at 25 C but
are unexcitable at 40 C. The absence of FHF2 accelerates the rate of closed-state and
open-state sodium channel inactivation, which synergizes with temperature-dependent
enhancement of inactivation rate to severely suppress cardiac sodium currents at elevated
temperatures. Our experimental and computational results identify an essential role for
FHF2 in dictating myocardial excitability and conduction that safeguards against
temperature-sensitive conduction failure.
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ever-induced arrhythmias1 and seizures2 are well docu-
mented, and are often associated with mutations in sodium
channels, suggesting that deficient sodium current reserve
is an important determinant for electrical instability during
hyperthermic states. Indeed, elevation in core body temperature
by fever or external heating3 is a known trigger for ventricular
fibrillation/malignant syncope in patients with Brugada
syndrome (BrS)4, an inherited arrhythmia condition diagnosed
by characteristic electrocardiographic (ECG) abnormalities in the
right precordial leads. Loss of function mutations in SCN5A,
which encodes the pore-forming subunit of the cardiac sodium
channel NaV1.5, have been identified in B20% of BrS patients5.
Biophysical analyses of mutant sodium channels from febrile
BrS patients have not identified a unifying mechanism for
the temperature-sensitive phenotype6,7. These data suggest that
factors in addition to SCN5A are playing important roles in
regulating the sodium current that ultimately predispose BrS
patients to fever-induced arrhythmias.
FHFs, also termed iFGFs, are a family of proteins that bind
to the cytoplasmic tails of voltage-gated sodium channels
(VGSCs)8–10, modulating channel inactivation and cellular
excitability11–13. We generated mice lacking fibroblast growth
factor homologous factor 2 (Fhf2KO) to study its role in regulating
cardiac excitability under normal and pathological states. Fhf2KO
mice have normal cardiac rhythm at baseline, but exhibit
temperature-sensitive electrocardiographic changes, including
coved-type ST elevations and progressive conduction failure
that is fully reversible upon return to normal body temperature.
Optical mapping reveals severe conduction slowing in mutant
hearts at 37 C that is further exacerbated by temperature
elevation. FHF2-deficient cardiomyocytes generate action
potentials upon current injection at 25 C but are unexcitable at
40 C. Loss of FHF2 results in a hyperpolarizing shift of
steady-state inactivation of the sodium current and accelerates
the rate of closed-state and open-state sodium channel
inactivation, which synergizes with temperature-dependent
enhancement of inactivation rate to severely suppress cardiac
sodium currents at elevated temperatures. Our experimental and
computational results demonstrate that FHF2 is a key regulator of
myocardial excitability, protecting the heart against conduction
failure under hyperthermic conditions.
Results
Derivation and validation of Fhf2KO mice. We engineered mice
bearing a deletion within the X-linked Fhf2 gene (Fig. 1a,b) in
order to test for possible effects on cardiac rhythm. The absence
of FHF2 protein in Fhf2KO mice was confirmed in immunoblots
of heart and brain tissue (Fig. 1c), and by ventricular myocyte
immunofluorescence (Fig. 1d). Notably, there was no noticeable
change in NaV1.5 protein levels or subcellular localization in
Fhf2KO ventricular myocytes. The IRES-lacZ insertion within the
Fhf2KO allele (Fig. 1a) allowed for whole-mount X-Gal staining of
the heart and demonstrated widespread Fhf2 gene expression in
atria, ventricles, and the His-Purkinje system (Fig. 1e).
Fhf2KO mice exhibit hyperthermia-induced conduction defects.
Female Fhf2KO/KO and male Fhf2KO/Y mice were viable and
fertile. Fhf2KO/Y mice exhibited normal baseline ECG parameters
























































Figure 1 | Derivation and validation of Fhf2KO mice. (a) Schematic of Fhf2WT and Fhf2KO alleles. The Fhf2KO allele differs from the Fhf2WT allele by the
replacement of a 570-base genomic segment spanning coding exon 3 with a cassette containing splice acceptor site, internal ribosome entry site,
a b-galactosidase coding sequence and residual loxP site. Positions and orientations of three PCR primers are indicated (blue arrowheads). (b) PCR
genotyping of Fhf2WT and Fhf2KO alleles. Simultaneous amplification of wild-type 350 bp and mutant 430 bp allelic segments were resolved on agarose gel.
(c) Immunoblotting of Fhf2WT/Y and Fhf2KO/Y tissue extracts. 40 mcg protein from Triton X-100-soluble fractions of brain and heart lysates were
electrophoresed and immunoblotted to detect FHF2 (top), NaV1.5 (middle) and GAPDH (bottom). The prominent B30 kDa species in Fhf2WT/Y heart
corresponding to the FHF2VY isoform are not detected in Fhf2KO/Y samples. (d) Immunofluorescence detection of FHF2 and NaV1.5 in Fhf2
WT/Y and
Fhf2KO/Y cardiomyocytes. Dissociated cells were fixed and probed with antibodies to FHF2 (red), NaV1.5 (red) and N-cadherin (green) along with DAPI
nuclear stain (blue). FHF2 and NaV1.5 colocalize to Fhf2
WT/Y striated T-tubules. NaV1.5 is comparably localized in the Fhf2
KO/Y myocyte, while FHF2 is not
detected. (e) Whole-mount X-Gal staining of a Fhf2LacZ/LacZ heart. LacZ at native sites of Fhf2 expression in targeted alleles (a) was detectable throughout
the heart, including atria (A), ventricles (V) and bundle of His (His). Higher magnification views of His bundle (black dashed box) and the left ventricular
free wall (red dashed box). Scale, 25 mm (d); 1 mm (e, left); 250mm (e, right).
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and functional assessments by transthoracic echocardiography
were also normal under euthermic conditions (Supplementary
Table 2). However, Fhf2KO/Y mice were highly temperature-
sensitive. Elevation of core body temperature by external heat
source resulted in marked conduction slowing as evidenced by
progressive P and QRS wave prolongation and atrioventricular
(AV) block (Fig. 2a and Supplementary Table 1). Above 40 C, all
mutant mice developed coved-type ST elevations with T wave
inversions, reminiscent of the Brugada pattern ECG (Fig. 2a).
Mutant mice did not tolerate sustained temperature elevation due
to high-grade AV block and progressive conduction failure.
With subsequent cooling to 37 C, all ECG conduction para-
meters returned to baseline. In contrast, male wild type
(Fhf2WT/Y) mice displayed normal ECG parameters throughout
the temperature ramp up to 43 C (Fig. 2a and Supplementary
Table 1). Measurement of intracardiac intervals including atrial-
His (AH) and His-ventricular (HV) intervals, which are measures
of AV nodal conduction time and His-Purkinje-mediated ven-
tricular activation time, respectively, were similar to Fhf2WT/Y
mice at 37 C but were significantly prolonged in mutant mice at
elevated temperatures (Fig. 2b and Supplementary Table 1).
Fhf2KO mice display increased sensitivity to flecainide. Fhf2KO/Y
animals were highly sensitive to the sodium channel blocker fle-
cainide (15 mg kg 1), which caused marked P and QRS wave
prolongation and AV block at 37 C (Fig. 2c and Supplementary
Table 3). In contrast, Fhf2WT/Y mice were able to tolerate
high dose flecainide (30 mg kg 1), and despite having marked
prolongation of P, PR and QRS durations, the conduction
parameters remained stable during temperature ramp up to 43 C
(Fig. 2d and Supplementary Fig. 1).
Isolated Fhf2KO hearts retain temperature-sensitive defects. To
rule out extra-cardiac contributions to the temperature-sensitive
phenotype, including autonomic effects, explanted Fhf2KO/Y and
Fhf2WT/Y hearts were Langendorff-perfused and subjected to a
temperature ramp protocol with a maximum perfusion
temperature of 43 C (Fig. 2e). Similar to the in vivo findings,
Fhf2KO/Y hearts exhibited progressive P and QRS wave
prolongation, and AV block on volume-conducted ECG with
temperature elevation. Coved-type ST elevations with T wave
inversions were again seen in mutant hearts at temperatures
greater than 40 C. Fhf2WT/Y hearts displayed stable conduction
parameters throughout the temperature recordings.
Optical mapping of Fhf2KO/Y and Fhf2WT/Y hearts using a
voltage-sensitive dye was performed to evaluate differences in
epicardial conduction velocities (CV) at 37 and 39 C. Activation
maps of the anterior wall were obtained at a pacing cycle length of
200 ms (Fig. 2f). Epicardial CV were markedly slower in Fhf2KO/Y
compared with Fhf2WT/Y hearts at 37 C (0.25±0.0063 m s 1
versus 0.56±0.01 m s 1, KO versus WT, respectively
P¼ 1.35E-5, Student’s t-test). CV slowing was global and not
confined to the right ventricular outflow tract, as has
been reported in some patients with BrS (refs 14–16). Fhf2KO/Y
hearts showed further reduction in epicardial CV at 39 C, while
Fhf2WT/Y hearts maintained stable epicardial CV measurements
at higher temperature.
Fhf2KO cardiomyocytes have reduced excitability at 40 C. To
study the effects of FHF2 on cellular excitability, we acutely
dissociated ventricular myocytes prepared from Fhf2WT/Y and
Fhf2KO/Y mice and tested their ability to generate action
potentials (AP) at 25 and 40 C in response to current injection
through whole-cell patch. Fhf2WT/Y cells could generate action
potentials at either temperature, although AP waveforms were
significantly attenuated at 40 C (Fig. 3a and Supplementary
Table 4). By contrast, Fhf2KO/Y cells had reduced amplitude AP
waveforms at 25 C and failed to fire at 40 C (Fig. 3a
and Supplementary Table 4). We conclude that the Fhf2KO
temperature-dependent conduction defect reflects, at least in part,
an underlying deficit in excitability of individual cardiomyocytes.
Altered sodium channel inactivation in Fhf2KO cardiomyocytes.
The basis of Fhf2KO cellular excitation deficit was probed by
recording sodium currents from voltage clamped Fhf2WT/Y and
Fhf2KO/Y cardiomyocytes. Voltage step commands elicited similar
transient sodium current densities in Fhf2WT/Y and Fhf2KO/Y cells
at 25 C, although peak currents in Fhf2KO/Y cells fell by 37% when
recorded at 30 C (Fig. 3b and Supplementary Table 4). Loss of
Fhf2 altered sodium channel inactivation in several ways. Channels
in Fhf2KO/Y cells underwent steady-state inactivation at more
hyperpolarized potential than did channels in Fhf2WT/Y cells at
25 C (Fig. 3c and Supplementary Table 4). Fhf2 deficiency also
accelerated the rate of sodium current decay when recorded at
either 25 or 30 C, with mutation and elevated temperature
combining to produce the fastest rate of open-state inactivation
(Fig. 3d and Supplementary Table 4). Sodium channel closed-state
inactivation rates were assayed by comparing peak sodium
conductance generated by voltage ramps to conductance generated
by instantaneous voltage step. While longer ramp durations
reduced peak sodium conductance under all conditions due to
closed-stated channel inactivation, higher temperature and Fhf2
mutation each enhanced the effect of ramp duration on channel
availability, with Fhf2 mutation and elevated temperature
combining to yield the most severe reduction in availability
(Fig. 3e, Supplementary Fig. 2 and Supplementary Table 4).
Sodium channel inactivation kinetics were further studied in
human embryonic kidney (HEK) cells transfected to express
cardiac sodium channel Nav1.5 with or without FHF2VY, the
principal protein isoform of FHF2 expressed in mouse heart13.
Patched HEK cells more easily survived temperature ramping than
did cardiomyocytes allowing assessment of Nav1.5 inactivation
parameters at 25, 35 and 40 C often within the same cell. Steady-
state voltage dependent Nav1.5 inactivation at 25 C occurred with
V1/2¼  82.2±1.6 mV (n¼ 7) in the presence of FHF2VY and
V1/2¼  93.5±0.9 mV (n¼ 9) in the absence of FHF2
(Po0.0002, Student’s t-test) (Supplementary Table 5). The
absence of FHF2VY also increased the rate of NaV1.5 closed-
state and open-state inactivation at all temperatures (Fig. 3f,g,
Supplementary Fig. 3 and Supplementary Table 5). Most notably,
even a 45 mV ms 1 voltage ramp at 40 C caused a greater than
50% reduction in Nav1.5 peak conductance in the absence of
FHF2, while more than 80% of channels remained available under
these conditions in the presence of FHF2VY (Fig. 3f and
Supplementary Fig. 3).
Computational models of Fhf2WT and Fhf2KO cardiomyocytes.
To establish whether hyperthermic excitation failure is
attributable to altered cardiac sodium channel inactivation gating,
we modified a previously generated mouse ventricular
cardiomyocyte computational model17 to reflect the differential
Nav gating properties in the presence and absence of FHF2. The
Fhf2WT and Fhf2KO myocyte models differed only in the open-
and closed-state inactivation rate constants of the embedded Nav
12-state Markov model. Both models generated the same peak
Nav conductance in response to step depolarization and the same
voltage dependence of Nav activation (Supplementary Fig. 4).
But in comparison to the Fhf2WT model, Nav conductance in
the Fhf2KO model displayed a hyperpolarizing shift in the
voltage dependence of steady state inactivation (Supplementary
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Fig. 4), exhibited faster closed-state inactivation in voltage ramp
simulations (Fig. 4a), and faster open-state inactivation
(Fig. 4b). Analogous to recorded channels, inactivation rates
were temperature-dependent, such that Fhf2 mutation and
temperature elevation combined generated the fastest Nav
inactivation rates (Fig. 4a,b, Supplementary Fig. 4). Current
injection simulations (Fig. 4c) demonstrated the consequences of
altered NaV inactivation gating. The Fhf2WT model fired action
potentials at both 25 and 40 C, although AP waveforms were
attenuated at higher temperature, while the Fhf2KO model
exhibited complete excitation failure at elevated temperature.
Discussion
Preservation of cardiac sodium current density is critical for survival.
Here we demonstrate that FHF2 acts to dampen the temperature-
dependent acceleration of NaV1.5 open and closed-state inactivation
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throughout a range of physiologically relevant body temperatures.
The importance of FHF2 becomes most apparent during
hyperthermia when the intrinsic inactivation kinetics of NaV1.5, if
left unchecked, can be brisk enough to severely impair sodium
current density, leading to excitation block and conduction failure.
Although the ECG parameters of Fhf2KO mice were normal at
37 C, the degree of conduction slowing measured by optical
mapping was substantial. This difference may reflect that in vivo
ECGs, unlike the optical maps, were measured during sinus
rhythm, where near simultaneous multi-site activation of the
ventricular myocardium by the His-Purkinje system can mask
myocardial conduction slowing. Purkinje myocytes express
additional FHF isoforms18, which may confer some degree of
protection against conduction slowing within the specialized
conduction system in Fhf2KO mice. The full extent of conduction
slowing observed in the isolated heart preparations may
also reflect the increased dependence of sodium current density
on the slope of initial membrane depolarization in Fhf2KO
myocytes. In the intact heart, action potentials are triggered
following non-instantaneous depolarization mediated by gap
junctional currents passing from upstream cells19. Therefore,
sodium current density in Fhf2KO hearts should be exquisitely
sensitive to conditions that increase intercellular resistivity
between cardiomyocytes, such as the increase in interstitial
volume that may be seen with Langendorff perfusion20. Indeed,
the observation that FHF2 may modulate the dependency of
sodium current density on junctional conductance has
important implications for arrhythmia mechanisms associated
with conditions that produce intercellular uncoupling, such as
acute ischaemia21 or pathologic gap junction remodelling22.
The dynamic nature of the ECG abnormalities in FHF2KO
hearts is highly reminiscent of Brugada syndrome, where ECG
parameters change from normal to coved-type ST elevations in
the presence of fever or sodium channel blocking drugs. While
the electrophysiological basis of the Brugada pattern ECG is
controversial, some have reported focal conduction slowing in the
right ventricular outflow tract as a potential mechanism14–16.
Although optical mapping of Fhf2KO hearts demonstrated global
conduction slowing, additional analysis may be revealing.
Furthermore, exploring the interplay between FHF2-dependent
alterations in sodium current physiology and other ionic currents
that have been implicated in the Brugada pattern ECG will
certainly be of significant interest.
It should also be noted that in contrast to our results, Puranam
et al.23 recently reported embryonic lethality in their lineage
of Fhf2KO mice. While the basis for this discrepancy is unclear,
one possibility is that this other reported mutant allele was
maintained on a C57Bl/6 background, with background
strain influencing phenotype. Whether this lineage of Fhf2KO
mice survives to adulthood in other background strains should
be evaluated.
In summary, our results identify the critical role of FHF2 in
maintaining adequate sodium current reserve in response to
hyperthermic stress. These results have direct implications for
fever-induced Brugada syndrome, where loss of function sodium
channel mutations may conspire with FHF-dependent
mechanisms, such as allelic expression levels, to produce
temperature-sensitive effects. It will be of interest to extend our
studies in Fhf2 mutant mice to additional fever models, such as
challenge with lipopolysaccharide24 or cytokines25,26. It is also
worth noting that the co-expression of FHFs and NaVs in the
heart and brain may point to a unifying theory for both febrile
arrhythmias and seizures23.
Methods
Fhf2KO mouse derivation. All protocols conformed to the Association for the
Assessment and Accreditation of Laboratory Animal Care and the NYU School of
Medicine Animal Care and Use Committee. A murine embryonic stem cell line
bearing a ‘knockout first with conditional potential’ cassette integrated into the
Fhf2 locus located on chromosome Xq26 (International Mouse Phenotype
Consortium, clone EPD0339_4_F09) was injected into blastocysts to derive
chimeric mice, which were outbred to establish viable mice bearing the targeted
allele. Pronuclear injection of Cre recombinase-expressing plasmid into fertilized
eggs of this lineage yielded progeny bearing Cre-mediated excision of Fhf2 coding
exon 3, which specifies an integral portion of the FHF b-trefoil fold10. The
Cre-excised allele specifies bicistronic transcripts encoding truncated FHF2
peptides (from exons 1 to 2) and E. coli LacZ (Fig. 1a). A 3-primer polymerase
chain reaction reaction with Phyre DNA polymerase allows simultaneous detection
of wild-type (WT) and knockout (KO) alleles (Fig. 1a,b). Mice carrying the KO
allele were backcrossed three generations to the 129/svPas strain before use in all
cardiac physiology experiments.
Antibody reagents. Immunofluorescence antibodies [target, dilution, (species,
company)]. Primary antibodies: FHF2 (ref. 27) 1:500 (Epitope GGKSMSHNEST,
Rabbit), NaV1.5 1:50 (mouse, Alomone, ASC-005), Sarcomeric Actinin 1:100
(mouse, Sigma, a7811), N-cad 1:100 (mouse, BD Biosciences, 610921). Mounting
medium with DAPI (Vectashield, H-1200).
Western blot antibodies. Primary antibodies: FHF2 1:1,000 (rabbit, Sigma,
HPA002809); NaV1.5 1:500 (rabbit, Alomone Labs. ASC-005); GAPDH 1:750
(mouse, Millipore: mab374). Secondary antibodies: Goat anti-Rabbit 1:15,000
(Li-Cor 926-32211); Goat anti-Mouse 1:15,000 (Li-Cor 926-32220).
Immunoblotting. Brain and exsanguinated heart tissues were homogenized in cold
detergent-free buffer, after which membranes were solubilized by adding 1% Triton
X-100. Clarified lysates were run on 4–20% precast polyacrylamide gradient gels
Figure 2 | Hyperthermia-induced electrocardiographic (ECG) changes and conduction block in the Fhf2KO/Y heart. (a) Representative surface ECG
traces of adult (8–12 wk) Fhf2WT/Y and Fhf2KO/Y mice subjected to hyperthermia-induction protocol. External heat lamp was used to raise core body
temperature from 37 to 43 C followed by cooling to 37 C (1 C min 1). Fhf2KO/Y ECG parameters were similar to Fhf2WT/Y animals at 37 C (n¼ 10) but
were significantly prolonged in mutant mice at elevated temperatures (Z40 C) (n¼ 9 mutants and 7 controls). Coved-type ST elevations and high degree
AV block with periods of ventricular asystole were noted in Fhf2KO/Y mice above 40 C. Fhf2WT/Y mice did not exhibit altered ECG parameters
at any temperature (37–43 C). QRS duration is plotted against core body temperature. (b) Representative intracardiac electrogram traces during
hyperthermia-induction protocol. Intracardiac conduction intervals (AH, HV, AVI) of Fhf2KO/Y were similar to Fhf2WT/Y animals at 37 C but were
significantly prolonged in mutant mice (n¼ 3) at elevated temperatures (Z40 C). HV interval duration is plotted against core body temperature.
(c) Flecainide (15 mg kg 1) challenge was performed in adult (8–12 wk) Fhf2WT/Y and Fhf2KO/Y mice (n¼ 5). Representative surface ECG traces five minutes
after administration of flecainide demonstrates significantly prolonged ECG parameters in Fhf2KO/Y compared with Fhf2WT/Y mice at 37 C (upper panels).
Representative surface ECG traces 15 min after administration of flecainide 15 mg kg 1 in Fhf2KO/Y showing progressive heart block (lower panel).
(d) Flecainide (30 mg kg 1) challenge was performed in adult (8–12 wk) Fhf2WT/Y mice in combination with the hyperthermia-induction protocol.
Representative surface ECG traces of flecainide treated Fhf2WT/Y mice (n¼ 5) at 37 C and 43 C. Fhf2WT/Y mice treated with flecainide did not exhibit any
further prolongation of conduction parameters with elevated temperature (37–43 C). (e) Langendorff-perfused Fhf2WT/Y and Fhf2KO/Y whole hearts (n¼4)
subjected to hyperthermia-induction protocol. Volume-conducted ECG recordings of isolated Fhf2KO/Y hearts recapitulated the in vivo findings.
(f) Representative ventricular activation maps from Fhf2WT/Y and Fhf2KO/Y at 37 and 39 C (n¼ 3). Hearts were paced at a 200 ms basic cycle length.
Isochrones are drawn 5 ms apart. AH, atrial-His; HV, His-ventricular; AVI, atrioventricular interval; CV, conduction velocity. Scale, 1 mm (f). Data represent
mean±s.e.m. *significant P values, Student’s t-test.
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Figure 3 | Temperature-dependent excitation failure and altered sodium channel gating in the absence of FHF2. (a) Ventricular cardiomyocyte
excitability. Superimposed voltage traces of representative patched Fhf2WT/Y and Fhf2KO/Y cardiomyocytes injected with depolarizing current
(0–480 pA in 40 pA steps) at 25 C and in the same cells after raising temperature to 40 C. All tested Fhf2KO/Y cells were inexcitable at 40 C.
(b) Cardiomyocyte NaV peak conductance (gNaV-peak). gNaV-peak following  120 mV to  35 mV depolarization step was measured for Fhf2WT/Y
and Fhf2KO/Y cells at 25 C and 30 C. (c) Cardiomyocyte NaV steady-state inactivation. Available gNaV at 25 C after 60 ms conditioning at  140 to
40 mV is expressed as fraction maximal gNaV. Vertical dashed lines indicate V1/2 inactivation in Fhf2WT/Y and Fhf2KO/Y cells. (d) Cardiomyocyte NaV
open-state inactivation rate. Superimposed representative traces (left) from Fhf2WT/Y (black line) and Fhf2KO/Y (grey line) cardiomyocytes at 25 C
(top) and 30 C (bottom) following depolarization to  35 mV. Fast exponential time constant (t) for decay of sodium current in response to voltage
step to  35 mV are plotted for Fhf2WT/Y and Fhf2KO/Y cells at 25 and 30 C (right). (e) Voltage ramp NaV inactivation in cardiomyocytes. gNaV-peak in
response to voltage ramps to  50 mV at different rates was expressed as percentage of gNaV-peak elicited by step depolarization (N ramp rate).
Slower ramp rates decrease gNaV–peak through closed-state inactivation, which is sensitized by both elevated temperature and Fhf2 mutation
(histogram). See Supplementary Fig. 2 for representative conductance traces. (f) Voltage ramp NaV1.5 inactivation with and without FHF2VY.
HEK cells transfected with NaV1.5±FHF2VY subjected to voltage ramps to  30 mV at different rates at 25, 35 and 40 C. NaV1.5 closed-state
inactivation is increased by slowed voltage ramp, temperature elevation and the absence of FHF2VY. See Supplementary Fig. 3 for representative
conductance traces. (g) NaV1.5 open-state inactivation. Fast t for NaV1.5 current decay was measured in cells±FHF2VY at 25, 35 and 40 C. Elevated
temperature and absence of FHF2VY each accelerate NaV1.5 open-state inactivation. Data represent mean±s.e.m. *significant P values (all P values in
Supplementary Tables 4 and 5); ns, not significant; Student’s t-test.
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(Invitrogen) and transferred to nitrocellulose (Bio-Rad) overnight at 4 C.
Nitrocellulose membranes were incubated in blocking buffer consisting of
PBS (NaV1.5) or TBS (FHF2) with Tween-20 (0.05%) and 5% nonfat dry
milk. Membranes were then incubated with specific primary antibodies
diluted in 5% nonfat dry milk in PBST/TBST (0.05%) overnight at 4 C followed
by wash steps and secondary antibodies (Li-Cor). Antigen complexes were
visualized and quantified with the Odyssey Imaging System (Li-Cor). The
uncropped western blot images shown in Fig. 1c are displayed in Supplementary
Fig. 5.
Cardiomyocyte enzymatic dissociation experiments. Cardiac cells were
dissociated from adult hearts that were Langendorff perfused and enzymatically
digested according to AfCS Procedure Protocols PP00000125. Mice were
heparinized (500 U kg 1) and killed with 100% carbon dioxide. Hearts were
surgically removed via thoracotomy and immersed in ice cold perfusion buffer
(composition (mmol l 1): 113 sodium chloride (NaCl), 4.7 potassium chloride
(KCl), 0.6 potassium phosphate monobasic (KH2PO4), 0.6 sodium phosphate
dibasic (Na2HPO4), 1.2 magnesium sulphate heptahydrate (MgSO4.7H2O),
12 sodium bicarbonate (NaHCO3), 10 potassium bicarbonate (KHCO3), 10 HEPES
buffer solution, 30 mM taurine, 5.5 mM glucose and 10 2,3-Butanedione monoxime
(BDM)). The aorta was cannulated and Langendorff perfused with perfusion buffer
at a constant flow rate of 3 ml min 1 for 3 min. The perfusate was then switched to
myocyte dissociation buffer (composition: 1 perfusion buffer, 10 mg Liberase TM
and 12.5 mM calcium chloride (CaCl2) at a constant flow rate of 3 ml min 1 for
8 min. Perfusate temperature was maintained at 37 C. Heart was removed, placed
in a dish containing 2.5 ml myocyte dissociation buffer plus 2.5 ml stop buffer 1
(composition: 1 perfusion buffer, 10% bovine calf serum, and 12.5 mM CaCl2),
and tissue above the atrioventricular ring was removed. Ventricles were teased into
several small pieces with fine forceps. Cellular dissociation was achieved by further,
gentle mechanical agitation via 15 ml transfer pipets. Quality of myocyte
dissociation was then assessed by counting myocyte yield and percentage of
rod-shaped myocytes. Only preparations with yields greater than 1 million cells
and 460% rod-shaped myocytes were used for further experimentation.
Cardiomyocytes were sedimented by centrifugation at 100g for 1 min in 15 ml
tubes. The supernatant was discarded after sedimentation and the pellet was
re-suspended in 10 ml of stop buffer 2 (composition: 1 perfusion buffer,
5% bovine calf serum, and 12.5 mM calcium chloride (CaCl2)) added to increasing
concentration of Ca2þ in 5 min intervals (þ 50 ml 10 mM Ca2þ (62 mM), þ 50ml
10 mM Ca2þ (112 mM), þ 100 ml 10 mM Ca2þ (212 mM), þ 30ml 100 mM Ca2þ
(500 mM) and þ 50ml 100 mM Ca2þ (1 mM)). Viability of myocytes was
reassessed using the above quality control guidelines. Only cell preparations that
passed these criteria were used for experimentation.
Immunocytochemistry. Dissociated ventricular myocytes were fixed in 4%PFA
for 5 min. Cells in suspension were spun onto slides using Shandon Cytospin II
(Speed 250 r.p.m., 2 min). Cells were blocked with 10% serum and 0.01% Triton in
PBS for 1 h, and then incubated with primary antibodies overnight. Cells were then
washed in PBS and incubated with secondary antibodies conjugated to Alexa Fluor
dyes (Invitrogen) for 1 h before mounting. Slides were coverslipped with
Vectashield mounting media with DAPI (Vector Laboratories). Stained cells
were visualized using a Leica TCS SP5 confocal microscope with Leica LAS AF
acquisition software.
Whole-mount staining for b-galactosidase activity. Tissues were collected in
ice-cold PBS and perfusion fixed for 1 h in fix solution (2% formaldehyde, 0.2%
glutaraldehyde, 0.02% Nonidet P-40 (NP-40), 0.01% sodium deoxycholate in PBS).
After fixation, tissues were rinsed in PBS three times and then stained overnight at
37 C in the dark with stain solution (5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6,
1 mg ml 1 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal), 2 mM
MgCl2, 0.02% NP-40, 0.01% sodium deoxycholate in PBS). Bright field images of
hearts were taken using the Zeiss Discovery V8 microscope equipped with a Zeiss
AxioCam Colour camera interfaced with Zeiss Zen 2012 software.
Mouse in vivo electrophysiology and flecainide drug challenge. ECGs were
obtained using subcutaneous electrodes attached at the four limbs (MP100,
BIOPAC Systems). 8–12 week-old, male mice were anaesthetised with inhaled
(2% v/v) isoflurane. Heart rate and core body temperature (rectal temperature
probe) were continuously recorded. Flecainide (15 mg kg 1 or 30 mg kg 1) was
Time (ms)
Fhf2WT at 25 °C Fhf2KO at 25 °CFhf2WT at 40 °C Fhf2KO at 40 °Cc
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Figure 4 | Computational models of Fhf2WT and Fhf2KO cardiomyocytes. The two models have the same gNaV–peak in response to instantaneous
depolarization steps (Supplementary Fig. 4) and the same NaV temperature-dependent kinetic scaling factor (Q10¼ 3, see Methods), and differ only in
their NaV inactivation parameters. (a) Voltage ramp NaV inactivation in cardiomyocyte models. Simulations were conducted at 25, 35 and 40 C.
NaV sensitivity to closed-state inactivation during slower voltage ramp is potentiated in the Fhf2
KO model at all temperatures, closely resembling NaV1.5
recordings ±FHF2VY (Fig. 3f). (b) NaV open-state inactivation rate. t for decay of sodium current in response to voltage step to  20 mV are plotted for
both models cells at 25, 35 and 40 C. Open-state inactivation is accelerated in the Fhf2KO model at all temperatures. (c) Model cardiomyocyte excitability.
100 ms current injections ranging from 0 to 600 pA (insets) were applied to Fhf2WT and Fhf2KO models at 25 and 40 C. Both models are excitable at 25 C,
but only the Fhf2WT model is excitable at 40 C, comparable to cardiomyocyte recordings (Fig. 3a).
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administered via intraperitoneal injection. ECG analysis was performed in an
unbiased fashion where 100 beats at each temperature endpoint were analysed
using LabChart 7 Pro version 7.3.1 (ADInstruments, Inc). Detection and analysis of
P wave, PR interval and QRS wave intervals were set to Mouse ECG parameters.
Intracardiac recordings were obtained in 8–12 week-old, male mice under
isoflurane anaesthesia (1.5% v/v) using an octapolar catheter (EPR-800, Millar
Instruments) placed via the right internal jugular vein for bipolar recordings at the
level of the His bundle. Intracardiac intervals were measured from the His bundle
catheter when the atrial, His, and ventricular electrograms were stable over 425
beats. Measurement of the AH interval was taken from the His bundle recording
from the onset of deflection from baseline of the local atrial electrogram to the
onset of deflection from baseline of the His bundle electrogram. Measurement of
the HV interval was taken from the onset of deflection from baseline of the His
bundle electrogram to the onset of deflection from baseline of the earliest
ventricular electrogram, whether on surface ECG or intracardiac recordings. Core
body temperature was initially maintained at 37 C and gradually elevated up to
43 C at a rate of 1 C min 1 using an external heat lamp.
Transthoracic echocardiography. Echocardiography was performed using the
Vevo 2,100 high-resolution ultrasound imaging system with a real-time 30 MHz
linear array scanhead (MS400) at a frame rate of 235 fps, a focal length of 8 mm,
and a 10 10-mm field of view (Visualsonics; Toronto, Canada). 8–12 week-old,
male mice were anaesthetised with 2% isofluorane, and hair was removed from the
chest using a depilatory cream (Nair; Church & Dwight Co, Inc; Princeton, NJ).
Warmed ultrasound transmission gel was placed on the chest and used to obtain
left ventricular endpoints of cardiac function. B-mode cardiac imaging was
conducted on transverse (short axis) plane. The papillary muscles were used for the
short axis imaging landmark. M-mode recordings of the left ventricle were also
recorded at the short axis B-mode imaging plane to obtain left ventricular function
and dimensions through the cardiac cycle. Heart rate was monitored and core body
temperature was maintained at 37.5 C using a heated platform and a hair dryer
throughout the procedure. Data analysis was performed on VisualSonics Vevo
2,100 V1.5.0 software (Visualsonics; Toronto, Canada). The following parameters
were measured using three cardiac cycles from short axis M-mode images: diastolic
and systolic left ventricular internal diameter, anterior wall thickness, and posterior
wall thickness. From these measurements, left ventricular ejection fraction, per cent
fractional shortening, stroke volume, and cardiac output were calculated within the
Vevo software.
Heart isolation and Langendorff perfusion. Male mice of 8–12 week-old were
heparinized (500 U kg 1) and killed with 100% carbon dioxide. Hearts were surgically
removed via a thoracotomy. While fully immersed in oxygenated (95% O2, 5% CO2)
Tyrode’s (composition (mmol l 1): NaCl 114, NaHCO3 25, dextrose 10, KCl 4.6,
CaCl2 1.5, Na2PO4 1.2, MgCl2 0.7), the aorta was cannulated and Langendorff
perfused at a constant pressure of 70 mm Hg. Perfusate temperature was initially
maintained at 37 C and increased by increments of 1 C to a maximum temperature
of 41 C (optical mapping) or 43 C (volume-conducted ECG). Perfusate temperature
was allowed to reach steady state between temperature ramps.
Optical mapping. High-resolution optical mapping experiments were performed
as follows: excised hearts from 8 to 12 week-old, male mice were initially perfused
with Tyrode’s solution to clear blood and stabilize the heart, followed by Tyrode’s
solution containing 10mM blebbistatin. Hearts were allowed to recover for 20 min
and then stained with the voltage-sensitive dye, Di-4-ANEPPS (Molecular Probes
Inc., Eugene, OR, USA). Light from green LEDs (530 nm; ThorLabs) was used as an
excitation source and the emitted light (620 nm long pass) was detected with 1
high-resolution CMOS camera (Mi-CAM Ultima-L;SciMedia) at 1,000 frames per s
in bin mode (100 100 pixels) with 14-bit resolution. Images were processed using
a custom software package.
Action potential recordings from adult cardiomyocytes. Excitability of acutely
dissociated ventricular cardiomyocytes from FHF2WT/Y and FHF2KO/Y mice was
conducted using a MultiClamp700 Amplifier, Digidata 1,440 analogue/digital
converter and Clampex10 software (Molecular Devices). Cells were placed in the
recording chamber under a Nikon Eclipse microscope and perfused with
carbogen-bubbled bath solution (115 mM NaCl, 26 mM NaHCO3, 3 mM KCl,
1.2 mM KH2PO4, 3 mM glucose, 2 mM myoinositol, 2 mM Na pyruvate, 7 mM
HEPES, 1.2 mM Mg2SO4, 2 mM CaCl2, 0.2 mM CdCl2 at pH 7.2) maintained at
25 C using an in-line heater (Warner Instruments). Patch pipettes were
pulled with a P97 Micropipette Puller (Sutter Instruments) to yield a resistance of
1–1.5 MO when filled with 120 mM K gluconate, 4 mM NaCl, 5 mM
KOH-buffered HEPES, 5 mM KOH-buffered EDTA, 15 mM glucose, 1 mM
MgSO4, 3 mM Mg-ATP, 0.1 mM Na-GTP at pH 7.2. Pipette approach to cell was
visualized using a 60 water immersion lens and infrared illumination with
differential interference contrast. Following tight seal formation and break-in to
achieve whole-cell access, voltage clamp depolarization steps were used to confirm
presence of large inward sodium current and measure capacitive current transients
before switching to current clamp mode. Steadily applied negative current was used
to set the amplifier-measured voltage to  85 mV, which was equal to  95 mV
membrane potential due to a 10 mV junctional potential between pipette and
bath solutions. Excitability was assessed by applying 200 ms injection sweeps of
continuous current ranging from 0 to 480 pA in 40 pA steps. Membrane voltage
recordings were high-pass filtered at 10 kHz and digitally acquired at 50 kHz. After
data acquisition, the bath temperature was ramped to 40 C over a 3–5 min
time span, and excitability was retested with the same protocol. Only cells for
which input resistance deviated less than 20% during temperature ramp were
included in analysis.
Nav1.5 currents in HEK cells. 293T human embryonic kidney cells previously
described in28, and displaying little or no endogenous sodium channel expression29
were transiently cotransfected with a 2:1 mixture of Nav1.5-expressing plasmid30,
and a pIRES2-ZsGreen bicistronic plasmid (Clontech) expressing ZsGreen and
mouse FHF2VY proteins. The same pIRES2-ZsGreen plasmid without FHF2
coding sequence served as control. Cells were trypsinized 3 h post-transfection,
seeded onto gelatinized coverslips, and were used for recording after 48 h. For
sodium current recordings, coverslips were transferred to recording chamber
containing carbogen-buffered bath solution (115 mM NaCl, 26 mM NaHCO3,
3 mM KCl, 10 mM glucose, 4 mM MgCl2, 2 mM CaCl2, 0.2 mM CdCl2, 3 mM
myoinositol, 2 mM Na pyruvate, 7 mM NaOH-buffered HEPES pH 7.2) at 25 C
and green fluorescent cells were whole-cell patched with pipettes filled with
104 mM CsF, 50 mM tetraethylamine chloride, 10 mM HEPES pH 7.2, 5 mM
glucose, 2 mM MgCl2, 10 mM EGTA, 2 mM ATP, 0.2 mM GTP and having
1–2 MO resistance. For all recording protocols, sodium current was isolated during
data acquisition by P/N subtraction of leak and capacitive currents (N¼  6).
To ensure voltage clamping during sodium channel activation was adequate, cells
were subjected to a 19-sweep series of voltage steps from a hold of  120 mV to
between  80 mV and þ 10 mV in 5 mV increments. As criterion for adequate
clamp, transient current peaks for all voltage commands were nested within the
larger current trace of a following or preceding voltage step command.
Steady-state channel inactivation protocol. To determine the voltage depen-
dence of steady state channel inactivation, a 19-sweep protocol used  120 mV
holding command, a 60 ms variable test voltage step ( 120þ 5(n 1) mV),
followed by a  25 mV reporting pulse.
Voltage ramp protocol. As a measure of closed state channel inactivation rate, a
10-sweep protocol used  120 mV hold command followed by depolarization to
 30 mV either instantaneously (voltage step) or as a ramp ranging in time from
2 ms (¼ 45 mV ms 1) to 18 ms (¼ 5 mV ms 1).
Temperature elevation. After recording at 25 C, temperature was ramped to
35 C and later to 40 C. At elevated temperatures, the cell was first tested as above
to ensure maintenance of tight clamp, after which the voltage ramp protocol was
conducted. For many cells, voltage ramp protocols could be successfully run at all
three temperatures (examples in Supplementary Fig. 3).
Sodium current recordings in adult cardiomyocytes. All INa recordings in
isolated cardiomyocytes were conducted in whole-cell configuration at 25 or 30 C.
Recording pipettes were filled with a solution containing (in mM): NaCl 5, CsF 135,
EGTA 10, MgATP 5, HEPES 15, pH 7.2 with CsOH. Cells were maintained in a
solution containing (in mM): NaCl 5, CsCl 112.5, TEACl 20, CdCl2 0.1, MgCl2 1,
CaCl2, 1, HEPES 20, Glucose 11, pH 7.4 with CsOH. To determine the peak current
voltage relation, 200 ms voltage pulses were applied to Vm  90 mV to þ 30 mV in
5 mV voltage steps, from a holding potential of Vm¼  120 mV. Interval between
voltage steps was 3 s. Steady state inactivation was determined by stepping Vm to
conditioning voltages of between  130 mV and  20 mV for 60 ms, followed by a
30 ms test pulse to Vm¼  20 mV to elicit INa. The steady state voltage-dependent
inactivation curves were fitted to Boltzmann’s functions. As a measure of closed
state channel inactivation rate, a 10-sweep protocol used  140 mV hold command
followed by depolarization to  50 mV either instantaneously (voltage step) or as a
ramp ranging in time from 2 ms (¼ 45 mV ms 1) to 18 ms (¼ 5 mV ms 1). All
recordings were obtained utilizing an Axon multiclamp 700B Amplifier coupled to
a pClamp system (versions 10.2, Axon Instruments, Foster City, CA).
Cardiomyocyte excitation parameters. Spike threshold was defined as the point
of accelerated upward voltage deflection at the base of a spike, mathematically
defined as the voltage when d2V/dt240 as determined using Clampfit software
(Molecular Devices).
Spike Vamplitude¼VpeakVthreshold: ð1Þ
Values for FHF2WT/Y versus FHF2KO/Y were assessed for significant difference by
two-tailed Student’s t test. The number of FHF2WT/Y versus FHF2KO/Y cells that
could spike and that failed to spike at 40 C was used to assess significant
difference by two-tailed Fisher Exact Probability test using an online calculator
(http://vassarstats.net/odds2x2.html).
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Cardiomyocyte passive properties. Capacitance of each cell was measured as
Cap ¼DV=Dq ð2Þ
where Dq is the current transient time integral to a negative voltage step command
DV. Leak conductance was measured as
gleak¼Istep=DVm; ð3Þ
where DVm is the steady-state change in membrane voltage in response to a
negative current clamp command Istep.
Cardiomyocyte sodium conductance density.
gNavPeak¼INavPeak= Vcom ENað Þ ð4Þ
where ENa is the sodium reversal potential and INavPeak is the peak inward current
in response to a voltage command Vcom within the linear ohmic range of the
current/voltage relationship.
Voltage dependence of steady state sodium channel inactivation. Peak sodium
current accompanying the  25 mV reporting pulse was measured at each test
voltage, and the fraction of channels available (not inactivated) at test voltage
equalled INa-peak(Vtest)/INa-peak(maximum). To obtain V1/2 and k values for
voltage dependence of steady state inactivation, current data were fitted to
Boltzmann equation:
f Vtestð Þ¼ 1þ eðV1=2VtestÞ=k
h i1
þC ð5Þ
Open-state sodium channel inactivation kinetics. Transient sodium current
decay from 90% current peak to baseline was fitted to a two-term exponential decay
function
IðtÞ ¼I1e t=tfast þ I2e t=tslow þC ð6Þ
where I1 and I2 are the fast and slow decaying components of the transient current.
The fast component I1 associated with decay constant tfast constituted between 70
and 100% of the total current in all analysed cells.
Closed-state sodium channel inactivation kinetics. Data from voltage ramp
protocols provided an estimate of closed-state channel inactivation rate as a
function of voltage ramp rate. For each ramp command at each time point, we
calculated
gNav¼INav= Vcom ENað Þ ð7Þ
yielding sodium conductance traces as shown in Supplementary Fig. 3. Similarly,
gNavPeak¼INavPeak= VcomðatPeakÞ  ENa
 
ð8Þ
from which was calculated
% maximal gNavPeak rampð Þ¼ 100gNavPeak rampð Þ=gNavPeak stepð Þ ð9Þ
Computational modelling. The Fhf2WT and Fhf2KO cardiomyocyte models were
generated by introducing modifications to the murine ventricular cardiomyocyte
model from Bondarenko et al.17. These changes included (1) adjusting membrane
capacitance to 70 pF to more closely match our recorded measurements,
(2) recalibrating the ‘leak’ conductances by dividing the inward rectifying postassium
conductance two-fold and replacing with an equal density of potassium conductance
to achieve nonspiking responses to current injections similar to cardiomyocyte
recordings (Fig. 4c), (3) changing the densities of ultrarapid-activating delayed
rectifier and rapid-activating delayed rectifier potassium conductances to
0.112 mSmF 1 and 0.234 mSmF 1, respectively, in order to obtain more
realistic post-spike repolarization and (4) replacing the fast sodium conductance with
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This NaV model is an adaptation of the 13-state model of Raman and Bean31,
with the blocked open state and consequent resurgent current omitted. All rate
constants were scaled by a thermodynamic factor






a ¼ AaQ1010^ðVmembrane VshiftÞ=Va ð15Þ
b ¼ AbQ1010^ðVmembrane þVshiftÞ=Vb ð16Þ
g¼AgQ10 ð17Þ
d¼AdQ10 ð18Þ
Parameter values shared by both Fhf2WT and Fhf2KO models are
Aa¼ 2.44375 ms 1, Ab¼ 0.01325 ms 1, Ag¼ 150 ms 1, Ad¼ 40 ms 1,
Va¼Vb¼ 6 mV, n1¼ 5.422, n2¼ 3.279, n3¼ 1.83, n4¼ 0.738, a¼ (Oon/Con)^0.25,
b¼ (Ooff/Coff)^0.25. For the Fhf2WT model, ACon¼ 0.001 ms 1, ACoff¼
0.108 ms 1, AOon¼ 1.05 ms 1, AOoff¼ 0.003 ms 1, and Vshift¼  58 mV, while
in the Fhf2KO model ACon¼ 0.054 ms 1, ACoff¼ 0.027 ms 1, AOon¼ 1.5 ms 1,
AOoff¼ 0.001 ms 1, and Vshift¼  61 mV. These parameter differences preserved
the voltage dependence of NaV activation in the models while causing a 7 mV
hyperpolarizing shift in voltage dependence of inactivation for the Fhf2KO model
(Supplementary Fig. 4) and accelerating closed-state and open-state inactivation
rates (Fig. 4a,b) compared with the Fhf2WT model.
Voltage–clamp and current–clamp simulations were run using the Myokit
software interface32 and were initiated with a 200 ms channel state equilibration
phase. Voltage–clamp simulations included single-step and double-step protocols
to measure voltage dependence of NaV activation and inactivation along with a
ramp protocol comparable to that employed for experimental recordings to assess
closed-state inactivation. For current-clamp simulations, an initial constant
negative current was applied to adjust membrane voltage to  95 mV before
adding positive current steps in multiples of 50 pA (0.7 pA pF 1).
Statistics. Quantitative values are expressed as mean and standard error of the
mean for each group. Two-tailed Student’s t test was used to compare differences in
continuous variables between mutant and control animals and cells. Po0.05 was
considered statistically significant. Sample size calculations were done using
preliminary data to design the experiment for measuring continuous variables.
Groups were constructed to detect a 30% difference between experimental and
control groups with a power of 90% and a significance level of 0.05. Experimental
groups were blinded until the endpoints were analysed. Animal studies were done
before genotyping ensuring blinded observations. The Prism statistical package
(version 6, GraphPad) was used for analyses.
Data availability. Cardiomyocyte computational model files are available for
download at the ModelDB portal (https://senselab.med.yale.edu/modeldb/).
The mouse lines will be made publicly available through a mouse repository.
All other data and materials are available upon corresponding author request.
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